The Imperative of High-Quality Randomized Controlled Trials in Homoeopathy

We are writing this letter through the columns of your esteemed journal, “International Journal of High Dilution Research”, to throw light upon the rich history and growing body of evidence of homoeopathic practice which is at a critical juncture. As we strive to establish a more evidence-based foundation for our practice, the quality of randomized controlled trials (RCTs) plays a pivotal role. It is therefore obligatory that we as homoeopaths prioritize the sampling, conduct, design and reporting of RCTs for ensuring the authenticity of our research findings. Certain tools at hand include the Consolidated Standards of Reporting Trials (CONSORT) guidelines that consist of a 25-item checklist, aimed at enhancing the clarity and quality of clinical trial reportings. While a number of randomized controlled trials (RCTs) constitute a CONSORT flow diagram, the specific article in question does not fully adhere to the CONSORT checklist [1]. On the other hand, TRIPOD provides a framework for reporting prediction model studies, ensuring greater consistency and accuracy in their presentation [2]. Subject inclusion and exclusion criteria are crucial components of randomized controlled trial (RCT) design. These criteria not only impact the study's conduct and interpretability, but also prioritize patient safety [3]. We believe that implication of the aforesaid elements into homoeopathic clinical trials are key points to be addressed and warrants further discussion.